Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective.

Simple item page
dc.contributor.authorLodise, Thomas P
dc.contributor.authorRodriguez, Mauricio
dc.contributor.authorChitra, Surya
dc.contributor.authorWright, Kelly
dc.contributor.authorPatel, Nimish
dc.contributor.orcidhttps://orcid.org/0000-0002-4730-0655
dc.date.accessioned2025-02-11T19:49:23Z
dc.date.available2025-02-11T19:49:23Z
dc.date.issued2021-10
dc.description.abstractINTRODUCTION: Approximately 3% of hospitalized patients with community-acquired bacterial pneumonia (CABP) develop healthcare-associated Clostridioides difficile infection (HCA-CDI). The validated Davis risk score (DRS) indicates that patients with a DRS >/= 6 are at an increased risk of 30-day HCA-CDI. In the phase 3 OPTIC CABP study, 14% of CABP patients with DRS >/= 6 who received moxifloxacin developed CDI vs. 0% for omadacycline. This study assessed the potential economic impact of substituting current guideline-concordant CABP inpatient treatments with omadacycline in hospitalized CABP patients with a DRS >/= 6 across US hospitals. METHODS: A deterministic healthcare-decision analytic model was developed. The model population was hospitalized adult CABP patients with a DRS >/= 6 across US hospitals (100,000 patients). In the guideline-concordant arm, 14% of CABP patients with DRS >/= 6 were assumed to develop an HCA-CDI, each costing USD 20,100. In the omadacycline arm, 5 days of therapy was calculated for the entire model population. RESULTS: The use of omadacycline in place of guideline-concordant CABP inpatient treatments for CABP patients with DRS >/= 6 was estimated to result in cost savings of USD 55.4 million annually across US hospitals. CONCLUSION: The findings of this simulated model suggest that prioritizing the use of omadacycline over current CABP treatments in hospitalized CABP with a DRS >/= 6 may potentially reduce attributable HCA-CDI costs. The findings are not unique to omadacycline and could be applied to any antibiotic that confers a lower risk of HCA-CDI relative to current CABP inpatient treatments.
dc.description.urihttps://doi.org/10.3390/antibiotics10101195
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8532985
dc.identifier.citationLodise T, Rodriguez M, Chitra S, Wright K, Patel N. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective. Antibiotics (Basel). 2021 Oct 1;10(10):1195. doi: 10.3390/antibiotics10101195. PMID: 34680776; PMCID: PMC8532985.
dc.identifier.issn2079-6382
dc.identifier.other34680776
dc.identifier.urihttps://hdl.handle.net/20.500.14303/873
dc.language.isoen
dc.publisherMDPI AG
dc.relation.ispartofAntibiotics
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectClostridioides difficile infection
dc.subjectantibiotics
dc.subjectcommunity-acquired pneumonia
dc.subjectomadacycline
dc.titlePotential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Lodise, Thomas P. Publications